|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2007. ACC-001
We, in collaboration with Wyeth, are also developing ACC-001, a
novel beta amyloid-related active immunization approach. ACC-001
is in a Phase 1 clinical study designed to study safety and
immunogenicity in patients with mild to moderate
Alzheimers disease. The ACC-001 approach is intended to
induce a highly specific antibody response to beta amyloid. The
goal is to clear beta amyloid while minimizing side effects such
as inflammation of the central nervous system. Initiation of
Phase 2 clinical trials has been targeted for 2007.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. ACC-001
We, in collaboration with Wyeth, are also developing ACC-001, a
novel beta amyloid-related active immunization approach. ACC-001
is in a Phase 1 clinical study designed to study safety and
immunogenicity in patients with mild to moderate
Alzheimers disease. The ACC-001 approach is intended to
induce a highly specific antibody response to beta amyloid. The
goal is to clear beta amyloid while minimizing side effects such
as inflammation of the central nervous system. During the course
of 2006, we anticipate generating sufficient data to enter into
Phase 2 clinical trials.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||